Bryan Dechairo serves as the Chief Technology and Innovation Officer at GeneDx. In his role Bryan oversees the company’s AI, Technology, and R&D innovation teams. He is responsible for driving operational excellence as the company enters the next phase of commercial growth.
Bryan brings over 30 years of experience in exploratory and commercial diagnostic businesses, driving the development of revenue-generating clinical innovations that enhance patient outcomes. Learn more about Bryan's leadership role at GeneDx.
Insights from
Bryan Dechairo

The latest GeneDx EHR release expands prenatal testing options, adds ultraRapid GenomeDx® duo and trio ordering, and brings helpful guidance into existing clinical workflows. Organizations must update their integration to access these capabilities.

Prenatal Exome-to-Genome Reflex gives providers a flexible way to begin with exome sequencing while preserving a seamless path to genome analysis when additional answers are needed—all from one order and one sample.

GeneDx's August EHR release introduces Exome-to-Genome Reflex ordering in Epic Aura and supported point-to-point EHR integrations, along with prior authorization enhancements that help providers reduce delays, minimize reorders, and keep genetic testing moving.

GeneDx has launched Easy Order, a guided Provider Portal experience designed to help providers submit eligible ExomeDx™ orders with CMA more efficiently, with fewer manual steps and more complete information from the start.

GeneDx is expanding accessibility to exome testing for children with developmental delay, intellectual disability, and epilepsy through a new online offering that connects eligible families with licensed healthcare providers for clinician-guided testing.
.png)
GeneDx has redesigned its exome and genome test reports to make results easier to find, understand, and discuss. See how the new format improves the experience while preserving the same trusted scientific interpretation.

Learn how GeneDx uses AI-powered variant prioritization through MIMI Ranker to help clinical teams analyze exome and genome sequencing results, surface clinically relevant variants, and support faster rare disease diagnosis.

GeneDx has expanded its ultraRapid genome sequencing portfolio with GenomeDx™ ultraRapid duo and trio testing for critically ill infants and children. By incorporating genetic data from one or both parents, these options help clarify genetic findings and support time-sensitive clinical decisions in NICU and PICU settings.

.png)





